2-([1,1'-biphenyl]-4-yloxy)ethan-1-amine | 125470-84-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-([1,1'-biphenyl]-4-yloxy)ethan-1-amine
• 英文别名: 2-([1,1'-Biphenyl]-4-yloxy)ethanamine；2-(4-phenylphenoxy)ethanamine
• CAS: 125470-84-0
• 化学式: C₁₄H₁₅NO
• mdl: MFCD06245965
• 分子量: 213.279
• InChiKey: BSDBRFAGCUJYJG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-([1,1'-biphenyl]-4-yloxy)ethan-1-amine 在 sodium hydride 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 、 mineral oil 为溶剂， 反应 32.33h， 生成 4-chloro-N-methyl-N-[2-(4-phenylphenoxy)ethyl]benzamide
  参考文献：
  名称：

  [EN] COMPOUNDS FOR USE AS APPETITE SUPPRESSANT
  [FR] COMPOSÉS À UTILISER COMME ANOREXIGÈNE

  摘要：

  本发明涉及具有抑制食欲作用的新化合物及其用作治疗疾病和疾病的药物，特别是代谢综合征的用途。

  公开号：

  WO2022053541A1
• 作为产物：
  描述：

  biphenyl-4-yloxy-acetic acid amide 在 二乙二醇二甲醚 、 diborane(6) 作用下， 生成 2-([1,1'-biphenyl]-4-yloxy)ethan-1-amine
  参考文献：
  名称：

  Discovery of a new series of 5-HT1A receptor agonists

  摘要：

  Starting from compounds previously identified as alpha(1)-adrenoceptor antagonists that were also found to bind to the 5-HT1A receptor, in an attempt to separate the two activities, a new series of 5-HT1A receptor agonists was identified and shown to have high potency and/or high selectivity. Of these, compound 13, which combines high selectivity (5-HT1A/alpha(1) = 151) and good agonist potency (pD(2) = 7.82; E-max = 76), was found to be the most interesting. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.01.030

文献信息

• Visible light-mediated Smiles rearrangements and annulations of non-activated aromatics
  作者：Connor A. Lawson、Andrew P. Dominey、Glynn D. Williams、John A. Murphy

  DOI：10.1039/d0cc04666c

  日期：——

  We report the first examples of radical cation Smiles rearrangements. A series of aryloxy alkylamines underwent spontaneous reaction, with the amino group displacing the ipso-alkoxy group through substitution, at ambient temperature and under photoactivation by visible light in the presence of an acridinium catalyst (5 mol%). The study was extended to 3-(2-methoxyphenyl)propan-1-amine derivatives,

  我们报告了自由基阳离子Smiles重排的第一个例子。一系列芳氧基烷基胺进行自发反应，其中氨基在through啶催化剂（5mol％）的存在下，在环境温度下和在可见光的光活化下，通过取代作用置换ipso-烷氧基。该研究扩展至3-（2-甲氧基苯基）丙-1-胺衍生物，其缺乏合适的ipso离去基团。在此，有效的环化作用导致甲氧基的置换和四氢喹啉的形成。
• Substituted heteroaryl- and phenylsulfamoyl compounds
  申请人：Hamanaka S. Ernest

  公开号：US20050288340A1

  公开（公告）日：2005-12-29

  The present invention is directed at substituted heteroaryl- and phenylsulfamoyl compounds, pharmaceutical compositions containing such compounds and the use of such compounds as peroxisome proliferator activator receptor (PPAR) agonists. PPAR alpha activators, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases, in mammals, including humans. The compounds are also useful for the treatment of negative energy balance (NEB) and associated diseases in ruminants.

  本发明涉及取代杂环芳基和苯基磺酰胺化合物，包含这些化合物的制药组合物和将这些化合物用作过氧化物酶增殖剂受体（PPAR）激动剂。PPARα激动剂，包含这些化合物的制药组合物，以及将这些化合物用于提高某些血浆脂质水平，包括高密度脂蛋白胆固醇和降低其他某些血浆脂质水平，如低密度脂蛋白胆固醇和甘油三酯，因此治疗由低高密度脂蛋白胆固醇水平和/或高低密度脂蛋白胆固醇和甘油三酯水平加重的疾病，例如动脉粥样硬化和心血管疾病，在哺乳动物中，包括人类。这些化合物还可用于治疗反能量平衡（NEB）和反刍动物相关疾病。
• Matrix metalloprotease inhibitors
  申请人：——

  公开号：US20030212067A1

  公开（公告）日：2003-11-13

  Compounds of the formula (I) 1 and their pharmaceutically acceptable salts inhibit matrix metalloproteases, such as stromelysin, gelatinase, matrilysin and collagenase, and are useful in the treatment of mammals having disease-states alleviated by the inhibition of such matrix metalloproteases.

  化合物的公式(I)1及其药学上可接受的盐，可以抑制基质金属蛋白酶，如stromelysin、gelatinase、matrilysin和collagenase，并且对于需要抑制这些基质金属蛋白酶的疾病状态的哺乳动物的治疗是有用的。
• Substituted Heteroaryl- and Phenylsulfamoyl Compounds
  申请人：Hamanaka S. Ernest

  公开号：US20060229363A1

  公开（公告）日：2006-10-12

  The present invention is directed at substituted heteroaryl and phenylsulfamoyl compounds, pharmaceutical compositions containing such compounds and the use of such compounds as peroxisome proliferator activator receptor (PPAR) agonists. PPAR alpha activators, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides such as atherosclerosis and cardiovascular diseases, in mammals, including humans. The compounds are also useful for the treatment of negative energy balance (NEB) and associated diseases in ruminants.

  本发明涉及取代杂环芳基和苯基磺酰胺化合物、含有该类化合物的药物组合物及其作为过氧化物酶体增殖物激活受体（PPAR）激动剂的用途。该化合物可以作为PPARα激动剂，含有该类化合物的药物组合物可用于提高某些血浆脂质水平，包括高密度脂蛋白胆固醇，并降低其他某些血浆脂质水平，如低密度脂蛋白胆固醇和甘油三酯，从而治疗低高密度脂蛋白胆固醇水平和/或高低密度脂蛋白胆固醇和甘油三酯水平加剧的疾病，如动脉硬化和心血管疾病，在哺乳动物，包括人类中使用。该化合物还可用于治疗反能量平衡（NEB）和反刍动物相关疾病。
• Substituted alpha-aminosulphonyl-acetohydroxamic acids as therapeutic
  申请人：Pfizer Inc

  公开号：US06090852A1

  公开（公告）日：2000-07-18

  Compounds of formula (I): ##STR1## where the substituents are as defined herein, and salts thereof, are matrix metalloprotease inhibitors.

  式(I)的化合物：##STR1## 其中取代基的定义如本文所述，以及其盐，均为基质金属蛋白酶抑制剂。